News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
463,241 Results
Type
Article (25602)
Company Profile (154)
Press Release (437485)
Multimedia
Podcasts (30)
Webinars (7)
Section
Business (125474)
Career Advice (448)
Deals (20721)
Drug Delivery (44)
Drug Development (79487)
Employer Resources (44)
FDA (12742)
Job Trends (9445)
News (235934)
Policy (19080)
Tag
Academia (1764)
Academic (1)
Accelerated approval (6)
Adcomms (28)
Allergies (82)
Alliances (34340)
ALS (93)
Alzheimer's disease (1358)
Antibody-drug conjugate (ADC) (122)
Approvals (12746)
Artificial intelligence (241)
Autoimmune disease (20)
Automation (10)
Bankruptcy (147)
Best Places to Work (8290)
BIOSECURE Act (12)
Biosimilars (65)
Biotechnology (121)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (270)
Cancer (2174)
Cardiovascular disease (165)
Career advice (393)
Career pathing (14)
CAR-T (151)
Cell therapy (399)
Cervical cancer (20)
Clinical research (65945)
Collaboration (709)
Compensation (422)
Complete response letters (22)
COVID-19 (2101)
CRISPR (34)
C-suite (206)
Cystic fibrosis (91)
Data (2169)
Decentralized trials (2)
Denatured (16)
Depression (46)
Diabetes (227)
Diagnostics (5296)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (17)
Drug discovery (101)
Drug pricing (24)
Drug shortages (11)
Duchenne muscular dystrophy (83)
Earnings (48180)
Editorial (20)
Employer branding (3)
Employer resources (42)
Events (74073)
Executive appointments (596)
FDA (13883)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (642)
Gene editing (93)
Generative AI (23)
Gene therapy (279)
GLP-1 (534)
Government (2342)
Grass and pollen (4)
Guidances (50)
Healthcare (13890)
Huntington's disease (23)
IgA nephropathy (28)
Immunology and inflammation (104)
Indications (29)
Infectious disease (2220)
Inflammatory bowel disease (141)
Inflation Reduction Act (2)
Influenza (44)
Intellectual property (82)
Interviews (63)
IPO (11028)
IRA (8)
Job creations (1517)
Job search strategy (351)
Kidney cancer (11)
Labor market (18)
Layoffs (295)
Leadership (7)
Legal (2396)
Liver cancer (65)
Lung cancer (317)
Lymphoma (145)
Machine learning (5)
Management (14)
Manufacturing (198)
MASH (62)
Medical device (9282)
Medtech (9282)
Mergers & acquisitions (10187)
Metabolic disorders (542)
Multiple sclerosis (75)
NASH (15)
Neurodegenerative disease (93)
Neuropsychiatric disorders (21)
Neuroscience (1871)
NextGen: Class of 2025 (3941)
Non-profit (2436)
Now hiring (19)
Obesity (259)
Opinion (140)
Ovarian cancer (71)
Pain (81)
Pancreatic cancer (79)
Parkinson's disease (146)
Partnered (14)
Patents (176)
Patient recruitment (113)
Peanut (43)
People (37827)
Pharmaceutical (35)
Pharmacy benefit managers (1)
Phase I (21216)
Phase II (29388)
Phase III (21304)
Pipeline (1098)
Policy (40)
Postmarket research (2078)
Preclinical (7717)
Press Release (31)
Prostate cancer (100)
Psychedelics (30)
Radiopharmaceuticals (245)
Rare diseases (345)
Real estate (2956)
Recruiting (16)
Regulatory (16105)
Reports (24)
Research institute (1870)
Resumes & cover letters (60)
Rett syndrome (5)
RNA editing (4)
RSV (33)
Schizophrenia (64)
Series A (121)
Series B (82)
Service/supplier (8)
Sickle cell disease (42)
Special edition (12)
Spinal muscular atrophy (143)
Sponsored (17)
Startups (2424)
State (1)
Stomach cancer (12)
Supply chain (37)
Tariffs (6)
The Weekly (14)
Vaccines (516)
Venture capitalists (24)
Weight loss (137)
Women's health (30)
Worklife (6)
Date
Today (114)
Last 7 days (746)
Last 30 days (2172)
Last 365 days (27785)
2025 (9044)
2024 (29698)
2023 (33567)
2022 (41716)
2021 (43606)
2020 (40108)
2019 (31110)
2018 (23333)
2017 (24108)
2016 (22182)
2015 (25904)
2014 (18739)
2013 (14190)
2012 (14848)
2011 (15245)
2010 (14308)
Location
Africa (369)
Alabama (44)
Alaska (3)
Arizona (120)
Arkansas (8)
Asia (28240)
Australia (5477)
California (5396)
Canada (1528)
China (474)
Colorado (228)
Connecticut (241)
Delaware (123)
Europe (64584)
Florida (716)
Georgia (172)
Idaho (40)
Illinois (352)
India (17)
Indiana (232)
Iowa (6)
Japan (142)
Kansas (78)
Kentucky (21)
Louisiana (6)
Maine (25)
Maryland (661)
Massachusetts (3949)
Michigan (132)
Minnesota (267)
Mississippi (1)
Missouri (57)
Montana (27)
Nebraska (17)
Nevada (46)
New Hampshire (52)
New Jersey (1412)
New Mexico (24)
New York (1498)
North Carolina (812)
North Dakota (7)
Northern California (2404)
Ohio (151)
Oklahoma (13)
Oregon (29)
Pennsylvania (1146)
Puerto Rico (8)
Rhode Island (18)
South America (489)
South Carolina (16)
Southern California (2062)
Tennessee (77)
Texas (808)
United States (19277)
Utah (149)
Virginia (118)
Washington D.C. (40)
Washington State (470)
West Virginia (1)
Wisconsin (38)
463,241 Results for "aci clinical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
April 2, 2025
·
5 min read
Press Releases
LG Chem and Acies Bio Collaborate to Advance Sustainable Production of Chemicals
December 5, 2024
·
4 min read
Press Releases
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
November 21, 2024
·
3 min read
Press Releases
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
December 11, 2024
·
7 min read
Press Releases
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
November 14, 2024
·
5 min read
Press Releases
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 18, 2024
·
7 min read
Press Releases
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024
·
6 min read
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein (a-syn) positron emission tomography (PET) tracer to identify patients with multiple system atrophy (MSA).
October 27, 2023
·
5 min read
FDA
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease.
June 27, 2023
·
8 min read
Drug Development
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development.
November 30, 2022
·
6 min read
1 of 46,325
Next
